Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MSF Wants Faster Deployment Of Ebola Vaccine At ‘Fair’ Price

A Global Emergency Stockpile Is Being Considered

Executive Summary

As stockpiles of Ebola vaccine are being built up around the world, Médecins sans Frontières has said more action is needed to ensure sufficient numbers of vaccinations are available for use in current and future outbreaks. 

You may also be interested in...



WHO Prequalifies Ebola Vaccine To Speed Up Availability In Africa

Following its recent EU approval, moves are under way to make Merck’s Ervebo vaccine available in countries at risk of Ebola.

WHO Steps Up Drive To Build Local Drug & Vaccine Production In Lower-Income Countries

The COVID-19 pandemic has underlined the need for less well-resourced countries to improve access to medicines, vaccines, medical devices and other health products by building their own production capacities.

Swiss Finally Beat EMA On New Drug Approval Times

More rolling reviews, a reduction in review rounds, and a rise in applications through two international regulatory collaboration initiatives were among the factors behind a reduction in new drug authorization times in Switzerland last year. However, “submission gaps” versus other regulators remain a problem.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS141311

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel